Peer-reviewed veterinary case report
Survival in dogs with brain tumors treated with or without lomustine
By Van Meervenne, S et al.·Published in Veterinary and comparative oncology·2014·Small Animal Clinic·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions.
- Species:
- dog
Plain-English summary
A group of 71 dogs with brain tumors were treated either with standard medications like corticosteroids and anti-seizure drugs or those same medications plus a chemotherapy drug called lomustine. The dogs that received only the standard treatment lived an average of 60 days, while those who also got lomustine lived about 93 days. Interestingly, the study found that female dogs tended to survive longer than male dogs, but other factors like age or the location of the tumor didn't seem to affect survival time. This suggests that while lomustine may help, the difference in survival isn't huge.
People also search for: dog brain tumor treatment · lomustine for dogs · dog seizure medication · how long do dogs live with brain cancer · female dog cancer survival rates
Abstract
Brain neoplasia is diagnosed in an increasing number of dogs. Consequently, there is a higher need for an effective treatment. Chemotherapy is considered in cases where surgery or radiation is not optional. The objective of this retrospective study was to evaluate the difference in median survival time (MST) of dogs with intracranial masses, treated symptomatically with corticosteroids and anti-epileptic drugs, compared with the same symptomatic treatment supplemented with lomustine. The records of 71 dogs with intracranial masses were retrospectively evaluated. Fifteen dogs were treated symptomatically with corticosteroids and anti-epileptics, and 56 dogs received additional therapy with lomustine. There was no statistically significant difference in MST between both groups, being 60 and 93 days, respectively. Age, duration of symptoms, intracranial localization of the mass and intra- or extra-axial localization had no influence on survival time. However, female dogs survived significantly longer than male dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22738696/